VIPR1 agonists(Vasoactive intestinal polypeptide receptor 1 agonists), VIPR2 agonists(Vasoactive intestinal polypeptide receptor 2 agonists), adrenergic receptor antagonists(Adrenergic receptors antagonists)

Therapeutic Areas

Urogenital Diseases

Active Indication

Erectile Dysfunction

Inactive Indication-

Originator Organization

Independence Resources Plc

Active Organization

Independence Resources Plc

Inactive Organization

Plethora Solutions Ltd.

License Organization-

Drug Highest PhaseApproved

First Approval Date

Denmark (01 Jan 1998),

Erectile Dysfunction

Regulation-

Structure/Sequence

Molecular FormulaC18H23N3O4S

InChIKeyOGIYDFVHFQEFKQ-UHFFFAOYSA-N

CAS Registry65-28-1

View All Structures (2)

Sequence Code 3952

The sequence is quoted from: *****

Clinical Trials associated with Aviptadil/Phentolamine mesylate

ISRCTN77251669

/ RecruitingPhase 4

An open label, pilot study to determine the effect of in-centre and at-home administration intra-cavernosal injections of Invicorp on male Erectile Dysfunction (ED) post radical prostatectomy

Start Date22 Aug 2022

Sponsor / Collaborator-

100 Clinical Results associated with Aviptadil/Phentolamine mesylate

100 Translational Medicine associated with Aviptadil/Phentolamine mesylate

100 Patents (Medical) associated with Aviptadil/Phentolamine mesylate

Literatures (Medical) associated with Aviptadil/Phentolamine mesylate

01 Sep 2010·BJU InternationalQ2 · MEDICINE

The anatomy of drug development: Invicorp®, a product before its time

Q2 · MEDICINE

Article

Author: Wyllie, Michael G

01 Oct 2008·BJU International

Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction.

Review

Author: Wyllie, Michael G. ; Dinsmore, W. Wallace

Erectile dysfunction (ED) is becoming an increasingly common problem and although oral therapies offer first-line treatment for many men, they are contraindicated or ineffective in substantial groups of patients. Intracavernosal injection (ICI) therapy is the most effective nonsurgical treatment for ED and offers an effective alternative to oral therapy. Sufficient arterial blood supply and a functional veno-occlusive mechanism are prerequisites in the attainment and maintenance of a functional erection. Invicorp (Plethora Solutions, London, UK) is a combination of vasoactive intestinal polypeptide (VIP) 25 microg and phentolamine mesylate 1 or 2 mg for ICI in the management of moderate to severe ED. The two active components have complementary modes of action; VIP has a potent effect on the veno-occlusive mechanism, but little effect on arterial inflow, whereas phentolamine increases arterial blood flow with no effect on the veno-occlusive mechanism. Clinical studies showed that Invicorp is effective in >or=80% of men with ED, including those who have failed to respond to other therapies and, unlike existing intracavernosal therapies, is associated with a very low incidence of penile pain and virtually negligible risk of priapism. We estimate that there are >5.9 million men in the USA alone for whom oral ED drugs are not a viable treatment option, and for whom Invicorp might offer a safe and effective alternative.

01 Apr 2000·IDrugs : the investigational drugs journal

European Society for Impotence Research--third meeting. 30 January-2 February 2000, Barcelona, Spain.

Article

Author: Adeniyi, A

The role of sildenafil (Viagra; Pfizer Inc) in a variety of indications, including spinal cord injury following prostatectomy, was presented. Results obtained by comparing different therapies were also presented. The role of sildenafil in long-term users of intracavernous and intra-urethral therapy was presented by at least two groups with interesting results. Conversely, a presentation on the role of intracavernosal therapy in patients who had failed to respond to sildenafil revealed thought provoking-findings. The anticipation by delegates of an opportunity to preview new therapy was also satisfied, at least in part, with presentations on Invicorp (Senetek plc), sublingual apomorphine (TAP Pharmaceuticals Inc), BAY-38-9456 (Bayer Yakuhin Ltd), and a yohimbine/arginine combination. MUSE therapy (VIVUS Inc) was also revisited. The various presentations on the treatment of erectile dysfunction revealed a trend towards a more practical approach.

100 Deals associated with Aviptadil/Phentolamine mesylate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	G04BE30	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Erectile Dysfunction	Denmark	Independence Resources Plc	01 Jan 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Erectile Dysfunction	Discovery	Germany	-	-
Erectile Dysfunction	Discovery	Germany	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis